Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)

Approximately 25% of MDS patients (pts) progress to AML; 15% of those with lower-risk, and up to 40-50% of those with higher-risk disease. Predicting those who are likely to progress to AML early in their disease course could directly impact treatment decisions: lower-risk pts with higher risk of AML transformation may be offered transplant, while higher-risk pts may be considered for AML-like therapy.